EMERYVILLE, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will hold a
conference call on Monday, October 13, to provide an update on the
Viprinex(TM) (ancrod) Phase 3 Trial Program for acute ischemic stroke.
Hosting the call will be Paul E. Freiman, president and chief executive
officer and Warren W. Wasiewski, chief medical officer.
-- Date: Monday, October 13, 2008
-- Time: 1:00 p.m. (ET), 12:00 p.m. (CT), 10:00 a.m. (PT)
-- Dial-in number: 877-440-5803 U.S. & Canada / 719-325-4942
Telephonic Replay: A playback of the conference call will be available
from 1:00 p.m. (ET) on October 13, 2008 to midnight (ET) on October 20,
2008. Replay number: 888-203-1112 U.S. / 719-457-0820 International
Pass code: 9164451
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.
|SOURCE Neurobiological Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved